Background
==========

Lung cancer is the leading cause of cancer-related mortality in the world \[[@B1]\]. Approximately 15% of lung cancer patients have pleural effusion at the time of initial diagnosis, and 50% develop it later in the course of their disease \[[@B2]\]. Differentiating malignant from nonmalignant pleural effusion is a critical problem, and conventional methods have proven inadequate \[[@B3]-[@B6]\]. Pleural fluid cytology has traditionally been the analytical method of choice for the detection of tumor cells in pleural fluid. However, sensitivity varies between 30% and 60% \[[@B7]\], and blindly obtained pleural needle biopsy specimens offer little additional sensitivity \[[@B8]\]. Although the presence of tumor cells in pleural effusion is a diagnostic marker of malignant pleural effusion (MPE), the probability of finding them is low. For negative cytology pleural effusion, some of the currently used indices, such as carcinoembryonic antigen, neuron-specific enolase and cytokeratin 19 fragments (CYFRA 21-1), have a certain extent of differential value; however, their specificity and sensitivity are limited \[[@B9],[@B10]\]. Therefore, searching for new indices is very important.

In addition to diagnostic issues, patients with MPE have a poor prognosis and are difficult to treat effectively \[[@B11]\]. Despite advances in treatment modalities, the overall survival (OS) is still very short. The present standard treatment is to evacuate the pleural fluid, followed by intravenous chemotherapy or intrapleural chemotherapy \[[@B12]\]. However, it was found that not all patients were benefited from the addition of chemotherapy, especially in patients with short OS. Therefore, prognostic assessment of the patient is essential. Hsu *et al*. proved that the expression level of angiogenetic biomarkers was significantly correlated with patient survival and pleural effusion control \[[@B13]\]. In addition, researchers in recent molecular and genetic profiling studies identified several markers as diagnostic and prognostic factors of lung cancer.

The improved understanding of pleural effusion immunopathogenesis could lead to the development of immunodiagnostic tools to facilitate its differential diagnosis. Investigators in large-scale studies have reported that lymphocytes play an important role in the pathogenesis of pleural effusion \[[@B14]-[@B17]\]. CD4^+^ T cells can be differentiated into interleukin 17 (IL-17)-producing T helper (Th17) cells. Th17 cells produce unique cytokines, including IL-17A, IL-17F and IL-22. These cytokines play a role in inflammation and cancers \[[@B18]-[@B21]\]. In previous studies, researchers have reported that the levels of IL-17 are elevated in pleural effusion \[[@B22],[@B23]\]. However, whether there is a significant difference in their expression level as well as in the relationship between pleural fluid IL-17 concentrations and the prognosis for patients with lung cancer have not been evaluated to date.

In our present study, we assessed pleural effusion of various etiologies in 123 patients to determine whether IL-17 pleural fluid could be used as a diagnostic indicator of lung cancer and a predictor of survival time. We found that IL-17 is elevated in malignant effusion caused by lung cancer, as well as being potentially predictive of survival outcome.

Methods
=======

Patients
--------

The study included 123 consecutive patients with pleural effusion who were recruited from the Nanjing Chest Hospital from January 2009 to December 2010. All cases of pleural effusion had a definite etiology documented by examination of effusion biochemistry, cytology, pleural biopsy, percutaneous biopsy, endoscopic examination and clinical follow-up. The characteristics of the patients are summarized in Table [1](#T1){ref-type="table"}. The patient group included 70 men and 53 women with a median age of 65 years. Of the total sample, 78 patients (63.4%) had MPE and 45 (36.6%) had nonmalignant pleural effusion. The OS time in patients with MPE was measured from the time of diagnosis to the date of death or the last follow-up.

###### 

**Patient characteristics**^**a**^

  **Variables**                 **MPE**       **BPE**       ***P*-value**
  ----------------------------- ------------- ------------- ---------------
  Patients, *n*                 78            45             
  Mean age (±SD), years         56.3 ± 12.5   55.6 ± 11.7   \>0.05
  Male/female                   36/42         34/11         \>0.05
  MPE                                                        
    Adenocarcinoma              67            ND             
    Squamous cell carcinoma     5             ND             
    Small-cell lung carcinoma   6             ND             
  BPE                                                        
    Tuberculous                 ND            28             
    Parapneumonic               ND            12             
    Heart failure               ND            5              
  Diagnostic method                                          
    Biochemistry                ND            30             
    Cytology                    50            ND             
    Pleural biopsy              6             8              
    Percutaneous biopsy         12            4              
    Endoscopic examination      10            3              

^a^BPE, Benign pleural effusion; MPE, Malignant pleural effusion; ND, No data.

This study was approved by the Ethics Committee of Nanjing Chest Hospital, and informed consent was obtained from each patient.

Diagnostic criteria for pleural effusion
----------------------------------------

The diagnostic criteria for MPE were as follows. Cytological evidence of malignant cells present in pleural effusion or in biopsy specimens. Tuberculous (TB) pleural effusion was diagnosed according to the following findings: identification of acid-fast bacilli in pleural fluid, caseous granulomas in a pleural biopsy specimen and a high level of pleural fluid adenosine deaminase (\>40 U/L) with an improvement of the pleurisy after anti-TB therapy. Parapneumonic effusion was characterized by any pleural effusion associated with pneumonia and response to antibiotics. Patients with pleural empyema were also included in this group. Effusions related to heart failure were collected from patients with documented heart failure but without neoplastic or other disease.

Sample collection and determination of IL-17 concentration
----------------------------------------------------------

Fresh pleural effusion specimens were collected before treatment and centrifuged at 1,500 × *g* for 10 minutes at -4°C. The supernatants were immediately stored at -80°C until use. The IL-17 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) with the commercial human IL-17 Ready-SET-Go! ELISA Kit (eBioscience, San Diego, CA, USA). All assays were run in duplicate, with dilutions as appropriate, and the technicians were blinded to clinical data.

Statistical analyses
--------------------

All statistical analyses of differences between malignant effusions and nonmalignant pleural effusion were performed using the Mann--Whitney *U* test. The diagnostic accuracy of IL-17 in discriminating between lung cancer with malignant and nonmalignant pleural effusion was compared by constructing receiver operating characteristic (ROC) curves. The optimum cutoff point from the ROC analysis was established by selecting the value that provided the greatest sum of sensitivity and specificity. Survival analyses were performed using the Kaplan--Meier method, and significant differences in survival rates were compared using the logrank test. The Cox proportional hazards regression model was used to compare the relative influence of different prognostic factors. *P* \< 0.05 was considered to indicate statistical significance.

Results
=======

Levels of IL-17 in pleural effusion
-----------------------------------

As shown in Figure [1](#F1){ref-type="fig"}, patients with malignant effusion exhibited higher IL-17 concentration than those with nonmalignant pleural effusion (20.49 ± 5.27 pg/ml vs. 13.16 ± 2.25 pg/ml; *P* = 0.004). Pleural fluid IL-17 concentrations in patients with malignant effusion were higher than in patients with TB effusion (20.49 ± 5.27 pg/ml vs. 17.43 ± 5.39 pg/ml; *P* = 0.021).

![**Levels of interleukin 17 in pleural effusion.** Malignant effusion exhibited higher interleukin 17 (IL-17) concentrations than in nonmalignant effusion and tuberculous effusion. \*compared with nonmalignant effusion group and TB effusion group, *P* \< 0.05 for both.](2047-783X-19-23-1){#F1}

Diagnostic value of IL-17 in malignant pleural effusion
-------------------------------------------------------

ROC curve analysis was carried out to assess the IL-17 concentrations in patients with MPE. The area under the ROC curve was 0.724 (95% confidence interval = 0.635 to 0.812). The best efficacy was observed at 15 pg/ml. Using a cutoff value of 15 pg/ml, IL-17 had a sensitivity of 79.5% (62 of 78 patients), specificity of 91.1% (41 of 45 patients), accuracy of 83.7% (103 of 123 patients), positive predictive value of 93.9% (62 of 66 patients) and negative predictive value of 71.9% (41 of 57 patients) (Figure [2](#F2){ref-type="fig"}).

![**Receiver operating characteristic curve of interleukin 17 for the differential diagnosis of malignant and nonmalignant effusion.** ROC, Receiver operating characteristic.](2047-783X-19-23-2){#F2}

Relationship between IL-17 concentration and clinicopathological factors in lung cancer patients with malignant pleural effusion
--------------------------------------------------------------------------------------------------------------------------------

After we confirmed that the IL-17 concentration was elevated in patients with MPE, we sought possible relationships between IL-17 and gender, age, histologic type of tumor, cancer stage, Eastern Cooperative Oncology Group performance status (ECOG PS), positive cytologic examination and location of pleural effusion. As shown in Table [2](#T2){ref-type="table"}, we found no significant correlation between IL-17 concentration and any of these clinicopathological factors.

###### 

**Interleukin 17 levels in pleural effusion of lung cancer patients**^**a**^

  **Clinical variables**   **Patients (*n*)**   **IL-17 (pg/ml) Mean ± SD**   ***P*-value**
  ------------------------ -------------------- ----------------------------- ---------------
  Age (years)                                                                 0.343
    ≥60                    38                   27.08 ± 4.87                   
    \<60                   40                   19.92 ± 5.28                   
  Gender                                                                      0.259
    Male                   36                   21.23 ± 5.30                   
    Female                 42                   19.87 ± 5.23                   
  Histologic type                                                             0.491
    Adenocarcinoma         67                   20.33 ± 6.12                   
    Nonadenocarcinoma      11                   21.52 ± 5.05                   
  ECOG PS                                                                     0.256
    0 or 1                 50                   19.99 ± 5.37                   
    2 to 4                 28                   21.41 ± 5.21                   
  Cytologic examination                                                       0.912
    Positive               60                   20.46 ± 5.18                   
    Negative               18                   20.62 ± 6.12                   
  Stage                                                                       0.706
    M1a                    54                   20.34 ± 4.58                   
    M1b                    24                   20.83 ± 6.01                   
  Location                                                                    0.751
    Right                  50                   20.34 ± 5.36                   
    Left                   28                   20.15 ± 4.97                   

^a^ECOG PS, Eastern Cooperative Oncology Group performance status; IL-17, Interleukin 17.

Prognostic significance of pleural fluid IL-17 for lung cancer patients with malignant pleural effusion
-------------------------------------------------------------------------------------------------------

The OS for all lung cancer patients in the current study was 6.7 months, and the 1-year survival rate was 21.8%. The prognostic significance of pleural fluid IL-17 concentration and other factors in patients with MPE was evaluated by univariate analysis (Table [3](#T3){ref-type="table"}). The cutoff value chosen for pleural fluid IL-17 concentration in lung cancer patients was 15 pg/ml. High pleural fluid IL-17 concentration, older age, late-stage disease and poor ECOG PS were factors associated with poor survival. The survival time in lung cancer patients with pleural fluid IL-17 concentrations below 15 pg/ml was significantly longer than in those with higher concentrations (OS 10.8 vs. 4.7 months; *P* \< 0.05) (Figure [3](#F3){ref-type="fig"}).

###### 

**Univariate analysis for overall survival in lung cancer patients with malignant pleural effusion**^**a**^

  **Parameters**        **Patients (*n*)**   **OS (months)**   ***P*-value**
  --------------------- -------------------- ----------------- ---------------
  Age (years)                                                  0.038\*
    ≥60                 38                   5.1                
    \<60                40                   9.4                
  Gender                                                       0.538
    Male                36                   8.7                
    Female              42                   6.2                
  IL-17 (pg/ml)                                                0.023\*
    ≥15                 26                   4.7                
    \<15                52                   10.8               
  ECOG PS                                                      0.011\*
    0 or 1              50                   9.4                
    2 to 4              28                   3.1                
  Histologic type                                              0.617
    Adenocarcinoma      67                   7.5                
    Nonadenocarcinoma   11                   5.3                
  Stage                                                        0.047\*
    M1a                 54                   8.6                
    M1b                 24                   4.2                
  Location                                                     0.636
    Right               50                   7.3                
    Left                28                   6.9                

^a^ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival. \*Significant difference.

![**Relationship between pleural fluid interleukin 17 levels and overall survival in lung cancer patients analyzed by Kaplan--Meier analysis.** The survival of lung cancer patients with pleural fluid interleukin 17 (IL-17) levels \<15 pg/ml was significantly longer than the survival of patients with levels ≥15 pg/ml (*P* \< 0.05).](2047-783X-19-23-3){#F3}

To test the prognostic value of pleural fluid IL-17 concentration, we performed multivariate analysis of prognostic factors using the Cox proportional hazards model. We found that pleural fluid IL-17 concentration (*P* = 0.007) had independent prognostic significance, whereas ECOG PS (*P* = 0.157), age (*P* = 0.545), tumor location (*P* = 0.362) and cancer stage (*P* = 0.734) lacked significant independent effects on survival (Table [4](#T4){ref-type="table"}).

###### 

**Multivariate Cox proportional hazards analysis for overall survival in lung cancer patients with malignant pleural effusion**^**a**^

  **Parameters**   **HR**   **95%CI**        ***P-*value**
  ---------------- -------- ---------------- ---------------
  Age (years)                                0.545
    ≥60            1                          
    \<60           1.263    0.593 to 2.689    
  IL-17 (pg/ml)                              0.007\*
    ≥15            1                          
    \<15           0.329    0.146 to 0.742    
  ECOG PS                                    0.157
    0 or 1         1                          
    2 to 4         0.653    0.778 to 4.745    
  Location                                   0.362
    Right          1                          
    Left           0.455    0.083 to 2.479    
  Stage                                      0.734
    M1a            1                          
    M1b            0.168    0.449 to 3.112    

^a^95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, Hazard ratio; IL-17, Interleukin 17. \*Significant difference.

Discussion
==========

To the best of our knowledge, this study is the first on pleural effusion in which IL-17 levels were investigated for their diagnostic and prognostic power simultaneously in lung cancer patients with MPE. Our findings suggest that profoundly elevated pleural fluid concentrations of IL-17 (≥15 pg/ml) measured at the onset of effusion correlated with shorter survival in lung cancer patients. Furthermore, multivariate analysis of prognostic factors identified pleural fluid IL-17 concentration as an independent prognostic factor for OS. These results suggest that IL-17 concentration measured in pleural effusion is an indicator of not only the presence of lung cancer but also the patient's survival outcome.

IL-17 is a proinflammatory cytokine produced mainly by CD4^+^ T lymphocytes. It may be important in tumor cell growth and may contribute to the aggressiveness of human tumors \[[@B24]\]. Recently, accumulating evidence has shown that IL-17-positive cells are frequently present in multiple cancers, including prostate cancer \[[@B25]\], colorectal cancer \[[@B26]\], hepatocellular carcinoma \[[@B27]\], breast cancer \[[@B28]\], ovarian cancer \[[@B20]\] and non-small-cell lung cancer \[[@B29]\]. Researchers in some studies have reported that IL-17 cell expression in MPE is elevated \[[@B15],[@B23]\]. Most of the reports indicate that IL-17 may protect against tumors by promoting immune system--mediated tumor rejection \[[@B30]\]. These results suggest the IL-17 plays an important role in tumor immune system evasion. One inference derived from this hypothesis is that IL-17 concentration in pleural effusion could be a good indicator in the follow-up of tumor patients, which is supported by our presently reported results.

Differentiating malignant from nonmalignant pleural effusion is a clinical problem, and conventional methods have proven inadequate \[[@B3]-[@B6]\]. A reliable marker for rapid and accurate diagnosis of pleural effusion is greatly needed. In this study, the IL-17 concentrations in malignant pleural effusion were higher than those in nonmalignant and TB pleural effusion. Our results suggest that IL-17 should be a tumor marker for the diagnosis of MPE. No statistically significant correlation was observed between IL-17 concentration and histological type of lung cancer. We assigned 15 pg/ml IL-17 in MPE as the diagnostic cutoff value, which had sensitivity of 79.5% and specificity of 91.1%. This result shows that IL-17 concentration could be a valuable marker in the differential diagnosis of malignant and nonmalignant pleural effusion. Further studies of the potential efficacy of this marker are needed.

Conclusion
==========

IL-17 concentrations in MPE associated with lung cancer are significantly higher than those in nonmalignant pleural effusion. Determination of IL-17 concentration in pleural effusion is diagnostically informative and IL-17 concentration is an independent prognostic factor that shows promise in the follow-up of lung cancer patients who develop pleural effusion.
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